Indian drugmakers' woes as US competition hots up and prices under pressure
Indian pharma majors selling copycat drugs in the USA are facing the heat given the steep competition and pricing pressure, and President Donald Trump's new policy on lowering drug prices, reports The Pharma Letter’s India correspondent.
The USA is an important market for Indian pharmaceutical makers constituting about 40.6% of the total $16.8 billion exports to the USA in fiscal year 2017.
With President Trump directing his top trade negotiator to strongly take up with all countries the fixing of prices of American pharmaceuticals, his description of drug price fixing by foreign countries as 'unjustified and done at the expense of America's research and development' has not gone down well with Indian government officials as well as domestic drug experts.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze